Pfizer-BioNTech COVID-19 Vaccine

Pfizer-BioNTech COVID-19 Vaccine

As of  November 9th 2020, Pfizer and BioNTech industries have announced the production of a vaccine that has passed the final ‘phase III’ of human round testing. Based on evidence from clinical trials, the Pfizer-BioNTech vaccine was 95% effective at preventing laboratory-confirmed COVID-19 illness in people without evidence of previous infection.

The Pfizer-BioNTech vaccine involves the injection of the virus’s genetic code, in the form of messenger RNA (mRNA), into human cells (the muscle of the upper arm) to stimulate the creation of the coronavirus’ spike protein; this protein is found to be the immune systems’ key target for coronaviruses. It does not contain eggs, preservatives or latex.

mRNA vaccines are a new type of vaccine to protect against infectious diseases.  In order to trigger an immune response, many vaccines put a weakened or inactivated germ into our bodies.  However, mRNA vaccines instead, teach our cells how to make a protein or even just a piece of a protein that triggers an immune response inside our bodies. This immune response, which produces antibodies, is what protects us from getting infected if the real virus enters our bodies.  At the end of the process, our bodies have learned how to protect against future infection.

The benefit of mRNA vaccines, like all vaccines, is those vaccinated gain this protection without ever having to risk the serious consequences of getting sick with COVID-19.

Read more here.